STEPHANIE KITCHEN: Open Payments
NPI 1750071056 · MADISON, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,525 in 183 payments from 17 companies in 2025. Trend: 2023 $998 · 2024 $3,193 · 2025 $4,525
Food & beverage: $4,525
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 33 | $839 |
| Vanda Pharmaceuticals Inc. | 25 | $771 |
| Alkermes, Inc. | 13 | $443 |
| Axsome Therapeutics, Inc. | 18 | $399 |
| Otsuka America Pharmaceutical, Inc. | 11 | $385 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $352 |
| ABBVIE INC. | 21 | $292 |
| Janssen Pharmaceuticals, Inc | 5 | $237 |
| E.R. Squibb & Sons, L.L.C. | 9 | $203 |
| Lundbeck LLC | 8 | $167 |
Products named: INGREZZA, FANAPT, REXULTI, Auvelity, CAPLYTA, VRAYLAR, ARISTADA, LYBALVI.
Industry payments across AL — which companies pay providers there.
